A Phase II, International, Multicenter, Open-label, Proof of Concept Study of BN83495 in Postmenopausal Women With Advanced, Metastatic or Recurrent Oestrogen Receptor (ER) Positive Endometrial Carcinoma Who Have Received One Line of Chemotherapy in the Adjuvant or Metastatic Setting.
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2015
At a glance
- Drugs Irosustat (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Ipsen
- 06 Jun 2011 Status changed from recruiting to discontinued.
- 07 Dec 2010 New trial record